agilon health, inc. (NYSE: AGL) stock experienced a significant drop of 5.07% in the pre-market trading session on Friday, following the release of its full-year results and analysts' revised forecasts.
The healthcare company reported revenue in line with expectations at $6.1 billion for the fiscal year. However, it reported a larger-than-expected statutory loss of $0.63 per share, which raised concerns among investors.
Analyst projections for the upcoming year have been revised, with revenue estimates lowered to $6.10 billion, approximately in line with the previous year. Additionally, analysts expect agilon health's revenue growth to slow substantially, projecting an annualized growth rate of 0.6% compared to the historical five-year growth rate of 38%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。